March 20, 2001 |
Irvine eye- and skin-care company Allergan Inc. said Monday that it has received U.S. Food and Drug Administration approval for its Alphagan P medicine for lowering intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Allergan said in a press release that two 12-month clinical studies showed that Alphagan P is comparable in efficacy to Alphagan with lower rates of certain adverse events.
December 16, 2005 |
Inamed Corp. said its board had unanimously approved Botox maker Allergan Inc.'s $3.2-billion offer in a deal that would allow Allergan to expand its wrinkle-treatment product line. Inamed, which also makes breast implants, said it hadn't signed the agreement, which wouldn't be finalized until Irvine-based Allergan said it was satisfied with its investigation of Inamed's wrinkle smoother Juvederm. Santa Barbara-based Inamed this week agreed to pay a $90-million breakup fee to end its $2.
September 7, 2002 |
Allergan Inc., maker of the Botox anti-wrinkle treatment, plans to raise as much as $350 million through the sale of debt securities, according to a document it filed Friday with the Securities and Exchange Commission. The Irvine company registered an offering to sell the securities when financing needs arise or market conditions become favorable.
September 4, 1998 |
Shares of Allergan Inc. climbed Thursday for the second consecutive day, following positive comments about the Irvine pharmaceutical company by Wall Street analysts. Merrill Lynch said the company's fundamentals "remain on an upswing." On Wednesday, Donaldson Lufkin initiated coverage of the company with a buy rating. Allergan's shares rose 9.5%, or $4.63, Thursday to $53.50 in active trading.
November 2, 2006 |
Allergan Inc., maker of breast implants and Botox anti-wrinkle treatment, said quarterly profit fell 29% because of restructuring expenses and costs associated with its acquisition of Inamed Corp. The Irvine-based company, which also makes eye medications, said third-quarter net income was $106.4 million, or 70 cents a share, down from $150.5 million, or $1.12, a year earlier. Before exceptional items, the company earned 95 cents a share.
May 25, 1993
Allergan Inc., a provider of eye-care and other medical products, said it has agreed to conduct joint clinical trials of drugs with Summit Technology Inc. The companies will conduct joint clinical trials of certain drugs for use after a surgical procedure known as photorefractive keratectomy. The procedure involves the use of a laser to correct eye disorders such as nearsightedness, farsightedness and astigmatism.